Please login to the form below

Not currently logged in
Email:
Password:

RDX5791

This page shows the latest RDX5791 news and features for those working in and with pharma, biotech and healthcare.

Latest Intelligence

  • Pharma deals during October 2012 Pharma deals during October 2012

    RDX5791 is an orally administered inhibitor of NHE3, a protein essential in the absorption of sodium in the intestines. ... 572. Ardelyx / AstraZeneca. Licence. RDX5791 for end stage renal and chronic kidney disease and IBS-C (phase II).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

How Far Do You Want To Go?
Join OPEN Health's virtual careers event on Tuesday 10th November, 15:00–17:00 GMT and discover where a career in medical communications could take you…...
"Fishbowl" Web Meeting for Internal POA Discussions: a Customer Story
Learn how our client successfully carried out a set of three virtual plan of action (POA) discussions, including one internal “Fishbowl” web meeting....
Whats the difference between patient engagement and patient experience?
We all talk a lot about patient engagement and patient experience. And sometimes, these terms are used interchangeably across the industry. But while they’re both important, they’re not the same....

Infographics